EPAS1 and neurodegenerative disease: This study implicates Hif2a in the Irp2−/− neurodegenerative disease mechanism as the cause of the energy metabolism shift from glycolysis to OXPHOS in vivo, and Hif2a may be a potential therapeutic target in the future.